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Background: Oslo University Hospital, Norway, had by autumn 2016, accumulated a waiting list of 101 patients with
obsessive-compulsive disorder (OCD) who had a legal right to receive treatment by a specialized OCD team. In this
challenging situation, the Bergen OCD-team suggested to solve the problem by offering all patients an option for the
rapid Bergen 4-day treatment (B4DT). The B4DT is an individual treatment delivered during four consecutive days in a
group of six patients with the same number of therapists. The approach has previously shown a post-treatment
response rate of 90% and a 3-month remission rate of 70%.
Methods: Ninety-seven of the wait-list patients were available for the scheduled time slots, and 90 received the
4-day format during 8 days (45 patients each week). The therapists were recruited from 22 different specialized
OCD-teams from all over Norway, and 44 (68%) had not previously delivered the 4-day format.
Results: Post-treatment; 91.1% of the patients were classified as responders, and 72.2% were in remission. At 3-
month follow-up; 84.4 were classified as responders and the remission rate was 67.7%. Oslo University Hospital
now offers the 4-day treatment as standard treatment for OCD.
Conclusions: We conclude that the B4DT is an acceptable and potentially effective OCD-treatment.
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In Norway, all patients with obsessive-compulsive disorder
(OCD) are granted empirically supported treatment by a
specialized OCD-team [1], and 30 teams have been estab-
lished since 2012. At Oslo University Hospital (OUH) the
consequence of this new rule of granted treatment was a
tripling of patients from 2014 to 2016, and more than 100
patients were waiting for treatment by the end of 2016.
The most probable reason is that many more OCD-
patients than previously applied for treatment when they
realized they might be granted empirically supported
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(http://creativecommons.org/publicdomain/zeexposure and response prevention (ERP) [2] where pa-
tients typically are treated over 12–16 weeks, the OCD-
team at Haukeland University Hospital, Bergen, has devel-
oped a novel treatment format where ERP is delivered
during just four consecutive days. Despite the relatively
brief treatment, the Bergen 4-day treatment (B4DT) has
been shown to yield a good outcome [3–5]. At post-
treatment assessment the proportion of responders varied
from 83% [4] to 93.8% [5] with a weighted mean of 89.4%.
At 6- or 12-month follow-up the mean response rate
was 82.4%. The post-treatment remission rate varied
between 73.8% [4] and 77.1% [3] with a weighted mean
of 76.0%, and at follow-up the average rate was 69.7%.
Also, the 4-day format has shown to be acceptable for
the patients and has a 'low drop-out rate; 0.7% (only 1
out of 142 patients; [3–5]. However, these studies havele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Kvale et al. BMC Psychiatry  (2018) 18:323 Page 2 of 9had small sample sizes (N = 35, 42, and 65) so larger tri-
als are warranted.
There are a few published studies on concentrated
ERP for OCD (using Yale-Brown Obsessive Compulsive
Scale as primary outcome measure) but no randomized
trial comparing it to weekly sessions of ERP. Franklin
et al. [6] and Abramowitz et al. [7] published uncon-
trolled effectiveness studies on concentrated ERP using
15 2 hour sessions over 4 weeks and 12 sessions of
90 min over 4 weeks, respectively. Hiss et al. [8] and
Lindsey et al. [9] published efficacy studies using 19 ses-
sions of 90 min over 4 weeks and 15 2 hour sessions
over 3 weeks, respectively. Finally, there are two
non-randomized comparison trials involving concen-
trated ERP. Abramowitz et al. [10] compared 15 2 hour
sessions over 3 weeks with 15 sessions over 8 weeks
(twice weekly) and found that the concentrated treat-
ment yielded a significantly higher proportion of recov-
ered patients post-treatment but not at 3-month follow-
up. Storch et al. [11] compared 14 sessions of 90 min
over 3 weeks with 14 weekly sessions and found no sig-
nificant differences at post- or at 3-month follow-up as-
sessment. Combining the Y-BOCS data for these six
studies (N = 266) yielded a weighted mean at pre-
treatment of 26.2 (SD 4.9) and at post-treatment of 11.9
(6.9), with a within-group effect size (Cohen’s d) of 2.42.
This can be compared to 2.06 for standard ERP in the
meta-analysis by Öst et al. [12]. Thus, previous versions
of concentrated ERP have used daily sessions of 90 or
120 min over 3–4 weeks, which is quite different to the
B4DT, consisting of four sessions of 3–8 h across four
consecutive days. Since longer versions of concentrated
ERP seem to yield somewhat better effects than standard
ERP it is possible that our highly concentrated version
yields even better effects.
The leader of the Bergen OCD-team (GK) was made
aware of the treatment delay problem at OUH and sug-
gested offering the 4-day treatment to patients on the
waiting list, which OUH accepted. The 4-day treatment
is best described as “individual treatment in a group
setting” since the ratio between therapist and patients
is 1:1 in groups which usually range from three to six
patients. In order to treat 100 patients, eight parallel
groups during two separate weeks would be needed. It
was decided to offer OCD-therapists from the other
specialized OCD-teams in Norway the opportunity to
participate, and by doing so to start their training in the
4-day format. This logistically demanding project of
treating 100 OCD-patients in 8 days was initiated dur-
ing the spring of 2017. The present paper reports on
the results.
Based on the outcomes of three previous effectiveness
studies from our team [3–5] we predicted that the out-
come of the present study would be equally good sincethe disorder and treatment were the same. Also, because
the three previous studies [3–5] on the B4DT were all
carried out with, to a large extent new therapists, we ex-
pected that the B4DT would be effective also with a sub-
stantial number of new therapists. Thus, the present
study can be seen as an example of systematic replica-
tion [13] having the purpose to test the outcome when a
large number of OCD-patients are treated at a new
clinic by new therapists.
Methods
Participants and procedure
In Norway, OCD-patients with a principal DSM-5 diag-
nosis of OCD [14] are entitled to empirically supported
treatment from an outpatient OCD-team. In February
2017, the 101 patients on the OUH waitlist were offered
the 4-day treatment. Inclusion criteria were a diagnosis
of OCD and patients had to be fluent in Norwegian. Ex-
clusion criteria included suicidality, psychosis, and active
substance abuse. Patients declining would receive stand-
ard care at OUH. Four were unable to attend due to
school obligations, work, and a prescheduled vacation
and 97 patients were scheduled (see flow chart in Fig. 1).
Patients referred to OUH had all been diagnosed with
OCD (by a psychiatrist or clinical psychologist at the
OUH OCD-team) and severity of OCD had been
assessed with a Y-BOCS interview before being placed
on the waiting list. Diagnoses were assessed using the
MINI International Neuropsychiatric Interview [15]. For
the present study, patients on the waiting list were for-
mally referred to the OCD-team in Bergen, and they
were re-assessed before starting treatment by using the
OCD entry questions from DSM-5 as well as another
Y-BOCS interview. This re-assessment was necessary as
some patients had been waiting for treatment for many
months. When formally referred to Bergen, patients
were asked to complete a number of questionnaires ad-
ministrated online (see measures) prior to the treatment,
and to complete these questionnaires post-treatment as
well as at 3-month follow-up.
Y-BOCS at post-treatment, as well as at 3-month
follow-up, were conducted over the phone by specially
trained clinical psychologists who worked at other
clinics and were not involved in the treatment. At
3-month follow-up, 20% of the sample was randomly se-
lected to be re-interviewed within 1 week by another in-
dependent psychologist. The inter-rater reliability, Intra
Class Coefficient (3.1) = 0.93, was excellent.
The treatment was conducted in Oslo by bringing in
therapists from all over Norway. Three of the 97 patients
became ill (two with flu, one with a minor bleeding
during pregnancy). One patient turned out to have se-
vere language problems, and three were misdiagnosed
(one had OCD-like symptoms which turned out to be
Fig. 1 Flow chart of study participants
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transsexual operation and the OCD-like symptoms were
related to this, and one patient had a primary diagnosis
of generalized anxiety disorder). Thus, the number of
OCD patients who received the 4-day treatment was 90.
All of these patients completed treatment so the attrition
rate was 0%.
Demographics
Mean age was 32.7 (SD = 9.7), 57% were women, and
58% single. A total of 78% were either working or study-
ing, whereas 22% received different social benefits. Mean
years of education was 12.6 (SD = 3.5). Thirty-two pa-
tients reported to have family members with OCD (see
Table 1 for details).
OCD severity and comorbidity
Mean pre-treatment score on the Yale-Brown Obsessive
Compulsive Scale (Y-BOCS) was 26.16 (SD = 3.37), 77%
had severe OCD (Y-BOCS score of 24–38), and 23% hada moderate OCD (Y-BOCS score of 18–23). A total of
86.7% had received previous treatment trials, but none
of the patients had received CBT for OCD with includ-
ing ERP procedures. Patients with previous therapy trials
(M = 26.25, SD = 3.47) did not differ significantly from
treatment naïve (M = 25.45, SD = 2.62), t(88) = 0.73, p
= .47. A total of 56 patients (62%) had one or more co-
morbid disorders (see Table 1 for details).
Pharmacological treatment
Forty patients used psychotropic medications: 35 used
antidepressants, one antiepileptic medication, eight
antipsychotics, four stimulants, five anxiolytics, three
hypnotics, and one received drug assisted treatment
for substance abuse. Patients with and without psycho-
tropic medication did not differ on Y-BOCS scores,
t(88) = .014, p = .99, GAD-7 scores t(88) = .41 p = .69,
or PHQ-9 scores, t(88) = 1.10, p = .27, at pre-treatment.
No changes were applied to medication, but the pa-
tients were informed that the use of anxiolytics was
Table 1 Demographic and diagnostic characteristics of the
sample (N = 90)
Demographics n (%)/ M (SD) Comorbidity
Age 32.70 (9.72) GAD 27 (30.0%)
Years of education 12.60 (3.46) Depression 20 (22.2%)
Female gender 51 (56.7%) Bipolar 1 (1.1%)
Single 52 (57.8%) Panic 14 (15.5%)
Working 51 (56.7%) Tourette 2 (2.2%)
Studying 19 (21.1%) Specific phobia 4 (4.4%)
Social benefits 20 (22.2%) Social phobia 11 (12.2%)
Previous treatment 79 (87.8%) BDD 1 (1.1%)
Psychotropic meds 40 (44.4%) Health anxiety 2 (2.2%)
GAF-S (0–100) 51.73 (5.50) Anorexia 1 (1.1%)
GAF-F (0–100) 57.54 (9.96) Bulimia 2 (2.2%)
Age at OCD onset 15.47 (6.55) ADHD 1 (1.1%)
Years with OCD 16.12 (10.40)
Note: GAF general assessment of functioning, GAD generalized anxiety
disorder, BDD body dysmorphic disorder, ADHD attention deficit
hyperactivity disorder
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were not receiving other treatment during the treat-
ment period.Preparing the patients for treatment
In order to ensure standardized information, patients re-
ceived written information and watched a video presenting
the outline of the 4-day treatment https://www.youtube.-
com/watch?v=nqx8knpy3i4 as well as a 6 minute descrip-
tion of the treatment made in 2014 by and broadcasted on
Norwegian national TV (NRK) https://www.youtube.com/
watch?v=ZRSExyZ3GPg. After accepting the treatment
offer, they watched the following video describing the
4-day treatment in more detail https://www.youtube.com/
watch?v=1Fnxt0_ljpY&t=1s.
The patients’ expectations of treatment outcome and
evaluation of the treatment credibility, were assessed
with an adapted version of the Borkovec and Nau [16]
Reaction to treatment scale (0–100%). A score below
100% on any of the four questions was taken as an
opportunity to clarify possible misunderstandings. The
patients were instructed to suggest exposure tasks, and
as guidance they were told that “exposures that their
OCD would appreciate the least” often were the most
relevant. During the week before treatment, the group
leader (see below) called each patient and performed
a standard interview, focusing on clarifying possible
misunderstandings and ensuring that the patients
understood that they were required to prepare
exposure tasks.Staffing the groups
In order to be able to treat 100 patients, two time slots
were selected with eight groups of six patients in each.
Therapists from 22 different OCD-teams in Norway
wanted to participate, as well as a Scandinavian-speaking
American colleague and three Icelandic psychologists.
Therapists with the most extensive OCD-experience
were given priority, as were therapists from teams that
would be able to participate in both time-slots. When
possible, the groups were staffed with 50% of qualified
4-day therapists, or therapists with at least one prior ex-
perience with the 4-day treatment. In order to qualify as
a 4-day therapist he or she must have participated in a
minimum of two 4-day groups and demonstrated com-
petency in the exposure procedure evaluated independ-
ently by two 4-day experts. All group leaders had acted
as therapists in minimum of six groups. In the Oslo case,
group leaders did not have responsibility for a given pa-
tient, but rather was responsible to ensure that all thera-
pists and patients received the necessary supervision,
intervention, and assistance. In each group, one of the
therapists also acted as “second in command”. Further-
more, each group had a person taking care of the logis-
tics. In total, 66 therapists (including group leader)
participated, 61 of them twice, and 44 of them without
prior experience with the 4-day format.Preparing the therapists for the 4-day treatment and
logistic
Groups were scheduled from Tuesday to Friday, and
therapists met the day before for 8 hours in prepar-
ation, including introduction to the psychoeducation
and a detailed outline of the 4-day treatment, given by
the developers, Bjarne Hansen (BH) and Gerd Kvale
(GK). Prior to this, all therapists received the same
introduction to the 4-day treatment as the patients.
The therapists also received all relevant information
regarding their patients. GK and BH had daily meet-
ings with each group leader and “second in command”
to ensure that potential challenges were dealt with in
accordance with the 4-day protocol.
Groups were located at different places at the OUH,
minimizing external disturbances related to the number
of parallel groups. Also, a centrally located “control
center” led by GK and BH and staffed with support
personnel was established.Treatment
The first of the 4 days (approximately 3 h) was allocated
to psychoeducation and to prepare individual exposure
tasks. The two middle days were dedicated to individually
tailored and therapist assisted exposure training (8–10 h
each day) in a wide range of OCD-relevant settings.
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the patients to actively approach whatever elicits the
relevant anxiety or discomfort, and to help them sys-
tematically use the anxiety and discomfort as a cue to
“LEan into The anxiety” (LET-technique) instead of
employing obvious or subtle avoidance. Typically, the
therapist serves as a coach in the beginning, gradually
leaving more responsibility to the patients. The thera-
pists work as a team, which means that the patients
are not necessarily working with the same therapist
during the 2 days of exposure (see below). Rather, the
team leaders allocate and reallocate therapists (during
frequent and brief team-meetings) to ensure that the
patients who are struggling are assisted by the most
experienced therapists.
The exposures were interspaced with brief group
meetings where each participant reported on how they
were doing, especially on how they were practicing the
LET-technique. The patients had individual exposure
tasks for the afternoon and evenings, and reported pro-
gression back to the therapist with the last contact
typically being at 9 p.m. Relatives and friends were in-
vited to a psycho-educative meeting (one for each group)
in the afternoon of day 3. The last day “lessons learnt”
were summarized and plans for the next 3 weeks of self-
administered exposures were made. The patients were
informed how to contact the health care provider if an
emergency situation should occur. The next 3 weeks,
the patients were encouraged to report online every day
on how they were practicing the LET-technique. The cli-
nicians read the reports, without being in contact with
the patients.
Three months after treatment, patients were invited to
an individual session (30 min, conducted by the Oslo
team) where their experiences in the period following
treatment were discussed, and the principles of the
LET-technique repeated. No exposure work was con-
ducted in this session.
Measures
Yale-Brown Obsessive Compulsive Scale, Y-BOCS;
[17, 18] a semi-structured clinical interview that con-
sists of 10 items (each 0–4) covering the severity of
both obsessions and compulsions, and is a standard
approach to assess OCD severity. The psychometric
properties of the interview are well established. Y-
BOCS has been found to be sensitive to change after
treatment (e.g., 8).
Patient Health Questionnaire-9, PHQ-9; [19] is a
frequently used self-administered screening instrument
consisting of nine questions each rated on a 0–3 scale. A
score of 10 or more is indicative of a depressive disorder
[20]. The psychometric properties of the instrument are
sound [20].Generalized Anxiety Disorder scale, GAD-7; [20] is a
self-administered screening instrument for symptoms of
generalized anxiety consisting of seven items each rated
on a 0–3 scale. The psychometric properties for the in-
strument are good [20].Benchmarking
As is customary in effectiveness studies we compared the
mean Y-BOCS score and remission rate of the present
sample and the average for published effectiveness studies
on ERP. In order to do a fair comparison, we selected
studies that had short-term follow-up assessment (3–
6 months post-treatment) as in the present study, and
used any format of ERP. The following studies were
included in the benchmarking analysis [21, 22, 23–25]
comprising a total of 381 patients fulfilling DSM-IV cri-
teria for OCD.Statistical analyses
Statistical analyses were performed with SPSS version
24.0. Repeated measures ANOVA for Y-BOCS was con-
ducted using pre-treatment, post-treatment, and follow-
up scores. Effect sizes were calculated with Cohen’s d,
defined as (Mpre – Mpost)/SDpre.
Treatment response was calculated based on the inter-
national consensus criteria [26] which requires a ≥ 35% re-
duction of the individual patient’s pre-treatment Y-BOCS
score in order to be classified as a clinically relevant re-
sponse. A patient is classified as remitted if the post-
treatment Y-BOCS score is ≤12 points. For Y-BOCS scores
there were no missing data at pre-treatment, whereas data
were missing for four patients at post-treatment and 12 at
follow-up. For PHQ-9 one case was missing at pre-
treatment and 10 at post-treatment. For GAD-7 there were
2 patients with missing data at pre-treatment and 10 at
post-treatment. Missing data were replaced using the
expectation-maximization method of SPSS, version 24.
The method was chosen to allow for repeated measures
ANOVA. All data presented are an integrated part of the
4-day standard quality control procedure.Results
Primary measures
Table 2 displays the results for Y-BOCS at pre-treatment,
post-treatment, and 3-month follow-up. Repeated mea-
sures ANOVA (Wilks’ Lambda) found a significant effect
of time, F(2) = 428.94, p < .001, partial Eta squared = .91.
Mauchly’s test of sphericity was not significant (p = .263).
A large effect size was observed with a Cohen’s d of 4.6
both at post-treatment and at follow-up. There were no
significant changes in symptoms from post-treatment to
follow-up assessment (p = .82).
Table 2 Means, standard deviations and effect sizes (Cohen’s d)




Post 10.54 4.61 4.63
3 months 10.68 6.31 4.59
GAD-7
Pre 11.88 4.88
Post 8.80 4.49 0.63
PHQ-9
Pre 11.75 5.36
Post 8.34 4.59 0.64
Note: N = 90. d = (Mpre – Mpost)/SDpre
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At post-treatment, 91.1% of the patients had responded
(≥35% improvement) and 72.2% were in remission
(≥35% reduction and Y-BOCS score of ≤12). At 3-month
follow-up, 84.4% had responded, and 67.8% were in
remission.
Table 3 shows the clinical improvement at post-
treatment and 3-month follow-up for the individual pa-
tients. Of the 65 patients who were in remission at
post-treatment, 51 patients (78.5%) were classified as in
remission at follow-up. Of the 17 patients who were
classified as responders at post-treatment, 6 had become
remitted at follow-up, 9 remained as a responder
whereas 2 had deteriorated to the category of no change.
Of the 8 patients who were classified as unchanged at
post-treatment, 4 were in remission at follow-up, and 4
remained unchanged.
Clinically significant change was also calculated for the
two severity subgroups. For the moderate subgroup,
76.2% were classified as remitted at post-treatment and
23.8% showed no change. At follow-up 81.0% were re-
mitted, 4.8% responded, and 14.3% showed no change.
For the severe/extreme subgroup; 71.0% were remitted
at post-treatment while 24.6% responded, and 4.3%
showed no change. At follow-up 63.8% were remitted,
20.3% responded, and 15.9% showed no change.Table 3 Comparison of clinical improvement rates at post-
treatment and follow-up
3 months follow-up
Remission Responded Unchanged Total
Post
Remission 51 6 8 65
Responded 6 9 2 17
Unchanged 4 0 4 8
Total 61 15 14 90Remission rates at post-treatment were not signifi-
cantly different between the two severity subgroups, χ2
(1) = 0.22, p = .64. The same was true at follow-up, χ2
(1) = 2.18, p = .14.
Depression and generalized anxiety
There were also significant decreases in symptoms of de-
pression and generalized anxiety from pre- to post-
treatment, equal to moderate effect sizes of .64 and .63
respectively (see Table 4).
Comparison with our previous studies
Table 5 shows a comparison of the Y-BOCS data be-
tween the present study and our previous three studies
[3–5] carried out in Bergen. The present sample of
OCD-patients starts at the same severity level as the pre-
vious samples and has very similar post-treatment and
3-month follow-up results. There are no significant dif-
ferences on Y-BOCS between the present and the previ-
ous samples at any time point.
Benchmarking
Table 6 shows the comparison between the present sam-
ple and standard ERP from published uncontrolled ef-
fectiveness studies. The Oslo patients, treated with the
Bergen 4-day treatment, had a significantly higher mean
Y-BOCS score at pre-treatment. However, both at post-
treatment and at 3-month follow-up their means were
significantly lower than the average for the published ef-
fectiveness studies. The remission rate was also signifi-
cantly higher for the Oslo patients than for the patients
in the effectiveness studies.
Discussion
The joint effort to erase the waiting list of more than
100 OCD-patients at Oslo University Hospital during 8
days worked well. In comparison, during the entire year
of 2016 OUH was able to treat 70 patients. Ninety-one
percent of the 90 patients treated with the 4-day format
responded at post-treatment, and 68% were in remission
at three-month follow-up.Table 4 Severity of anxiety and depression at pre-treatment,
post-treatment, and 3-months follow-up
GAD-7 PHQ-9
Severity Pre Post Pre Post
None 5 (5.6%) 13 (14.4%) 6 (6.7%) 15 (16.7%)
Mild 22 (24.4%) 43 (47.8%) 25 (27.8%) 42 (46.7%)
Moderate 37 (41.1%) 24 (26.7%) 32 (35.6%) 25 (27.8%)
Severe 26 (28.9%) 10 (11.1%) 27 (30.0%) 8 (8.9%)
Note: Pre Pre-treatment, Post Post-treatment. Cut-offs used for both GAD-7 and
PHQ-9 were 0–4 (none), 5–9 (mild), 10–14 (moderate), 15 and above (severe)
Table 5 Comparison the 4-day treatment studies on Y-BOCS












N: 35 42 65 90
Pre 26.1 (4.3) 25.7 (4.3) 25.8 (4.7) 26.2 (3.4)
Post 9.0 (4.8) 10.8 (3.9) 10.2 (5.1) 10.5 (4.6)
3 months 10.6 (7.0) ─ 10.5 (5.9) 10.7 (6.3)
6 months 10.3 (5.7) 12.2 (6.4) ─ ─
1 year ─ ─ 10.6 (7.0) ─
4 years 9.9 (7.4)
Note: The 4-year time point pertain to the combination of the Havnen et al.
2014 and 2017 studies
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on the 4-day format in our previous effectiveness studies
[3–5]. Furthermore, we have documented that the
changes are maintained at 1-year follow-up [5] and at
4-year follow-up [27]. Compared to standard ERP treat-
ment approaches, the 4-day format has a number of po-
tential advantages. It has a low declining rate and attrition
rate. Moreover, this treatment may have a significantly lar-
ger response rate and remission rate at post-treatment
compared to standard ERP in effectiveness studies.
In the present study we demonstrated that we were
able to upscale, and to help 90 moderately to severely af-
fected OCD-patients in 8 days; 45 in each 4-day slot.
This was done as a part of the public mental health care,
with no selection of patients.
The 4-day format is often labelled “individual treat-
ment in a group setting” indicating that the ratio be-
tween therapists and patients is 1:1. Basically, this means
that each therapist is able to treat one patient in less
than a week, which probably is highly cost-effective. All
the participating therapists were experienced in treating
patients with OCD using CBT, but 67% of them hadTable 6 Comparison between the Bergen 4-day treatment and
standard ERP in effectiveness studies
Bergen 4-day Effectiveness Statistic
N M (SD) N M (SD) t-test (p)
Y-BOCS
Pre 90 26.2 (3.4) 381 24.4 (5.4) 3.02 (=.0026)
Post 90 10.5 (4.6) 374 18.2 (7.0) 9.93 (<.0001)
3 months 90 10.7 (6.3) 317 16.2 (8.1) 5.95 (<.0001)
Remission Fisher’s test
Post 90 72.2% 110 35.5% p < .0001
3 months 90 67.8% 110 45.5% p = .0017
Note: Data for effectiveness studies were taken from uncontrolled studies of
ERP having 3–6 month follow-up. N indicates the total number of participants
across these studies. Remission was calculated as ≥35% reduction of pre-
treatment Y-BOCS scores and ≤ 12 on post and follow-up Y-BOCSpreviously not worked with the 4-day format and the
clear majority of the therapists had never worked
together before. Since each group is staffed with as many
therapists as patients, the format serves as a good
opportunity to work side-by-side with, and observe ex-
perienced 4-day therapists, and to get hands-on supervi-
sion. While model learning with hands-on supervision is
an obvious approach for physicians who are going to
learn surgery or any other medical discipline, it is rare in
the mental health care. It is a unique experience to be
able to observe six patients with OCD going through
major changes in only 4 days. After the Oslo experience,
all teams involved have asked to be fully trained in order
to deliver the 4-day format.
There are different limitations of the current study.
Evaluations of this treatment format has so far only been
tested using open trial designs, which do not compare
the effect of treatment with other established treatments
or placebo control. A RCT is necessary to draw defini-
tive conclusions about the efficacy and specificity of the
4-day treatment. Also, participants had not previously
received evidence based treatment for OCD. This could
limit generalizability of the findings. However, the
present study was aimed at ordinary OCD-patients, not
those who are treatment resistant. The study design and
study population could be possible explanations for the
good results. Another possible explanation is that the
current concentrated format is different from that used
in previous studies of concentrated treatment. They have
used daily sessions of 90–120 min across 3–4 weeks,
while we used 4 days and 3–8 h sessions. Longer
sessions in highly concentrated ERP could yield better
effects than standard ERP. Another issue concerns
missing data as 13% of participants did not provide data
at follow-up.
The present study tentatively indicates that the 4-day
treatment can yield good outcome at another site than
the originators’ place of work. Whether it works as well
for other research groups and in other countries remains
to be tested in future studies. However, the treatment is
currently being tested in Iceland and an uncontrolled
pilot study [28] obtained equally good effects as the ori-
ginal studies in Norway [3–5].
This approach has been developed as an integrated
part of the specialist health care with severely affected
patients and with virtually no bias in the selection of
cases that are offered the treatment. Since clinical
changes that are achieved during a very brief window of
time are large, seen in a large majority of patients, and
to a large extent are maintained at follow-up, we argue
that the 4-day treatment might offer a unique longitu-
dinal and nearly experimental approach to study basic
mechanisms of brain plasticity. Because no other factors
apart from treatment are of influence during the 4 days
Kvale et al. BMC Psychiatry  (2018) 18:323 Page 8 of 9of intervention, it is an ideal setting for studies using
functional magnetic resonance brain imaging (fMRI) or
biomarkers of e.g. epigenetic changes to elucidate func-
tional and structural changes on a number of different
explanatory levels [29, 30]. This is an interesting area for
future research which should be pursued.
Conclusions
In sum, the Bergen 4-day treatment for OCD showed
promising results. Future studies should test this treat-
ment format using a RCT design.
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